

Guidelines for Supplement Publication in the Canadian Journal of Cardiology

Supplements to the Canadian Journal of Cardiology (CJC) are designed to serve an educational purpose for the subscribers and readers of the Journal and other healthcare professionals. The goal of supplement publications is to provide fair, balanced information of high scientific quality. Supplements to the Journal are produced through the financial support of medical education companies, pharmaceutical companies, device and equipment companies, non-profit and governmental organizations, and their designates. The following are general guidelines for consideration, editorial handling, and publication of supplements:

1. Organizations considering publication of a sponsored supplement should first provide a written proposal to the Editor-in-Chief of the Journal for assessment and potential approval. The proposal should include:
 - a) Information about the scope and subject matter.
 - b) Any pertinent information about the background (e.g., specific name and location of any symposia on which the supplement is based).
 - c) A tentative list of proposed papers and authors.
 - d) A brief explanation of the rationale for the supplement, its scientific/educational objectives, and why it will be of interest to the readers of the Journal.
 - e) A time frame for submission of the supplement and an indication of the desired time frame for publication.
 - f) The name(s), affiliations, possible conflicts of interest, and contact information for any proposed Guest Editor(s). In the event that the supplement is to be handled by Guest Editors, the Guest Editors will be responsible for reviewing all papers in the supplement and ensuring their appropriateness as well as their conformity with journal guidelines prior to formal submission and editorial assessment by the Journal. Guest Editors will be responsible for submitting papers for consideration by the editorial board, will receive feedback from the Editor-in-Chief and/or his/her designate, and will communicate with authors to ensure that the recommendations are followed for revision. The Guest Editors will then resubmit revised manuscripts for final approval.
2. All articles in supplements must follow journal guidelines and will be subject to peer review by the editorial board of the Journal and/or external referees prior to acceptance.
3. Supplements must have educational value and be useful to the Journal readership to be considered for publication.
4. Supplements should primarily emphasize scientific topics (diseases/disorders, e.g., CAD or congestive heart failure, rather than specific drugs). Supplements devoted to classes of drugs rather than a specific agent will be given priority. In general, product-oriented publications will not receive serious consideration unless there are compelling reasons or unique scientific properties of the drug (product) that justifies its publication. The topic must be treated in an impartial, unbiased manner.
5. The authors are solely responsible for the content of their manuscripts and the opinions expressed. They are also responsible for the replicability, precision, and

integrity of the data. All authors are required to fully disclose any financial relationship with a company that has a direct fiscal or financial interest in the subject matter or products discussed in submitted manuscripts, or with a company that produces a competing product.

6. Authors are required to disclose the name of any company that has provided any editorial support in the development of their manuscript. In addition, they are required to disclose any funding that company may have received for manuscript development. If writing assistance was provided by persons who do not meet the criteria of authorship as described in the International Committee of Medical Journal Editors (<http://www.icmje.org/#author>), the authors must disclose the identity of the individuals who provided this assistance and the entity that provided any financial support of this assistance.
7. All supplement manuscripts will undergo editorial and/or peer review as determined by the Journal editorial office to consider the overall educational value of the manuscript and the scientific validity and reliability of new (not previously published) data (rationale/background; purpose; patients; location; experimental design; intervention(s); results; conclusions; etc.). Manuscripts determined to be unacceptable after the review process will be rejected for publication.
8. Sponsorship and support will be disclosed on the supplement cover or supplement front matter pages. Organizers and sponsors will be responsible for complying, and agree to comply, with all federal, state, and local laws, rules, and regulations that may be applicable in connection with sponsorship and support of the supplement. Advertising within the supplement will not be permitted.

For information on pricing and distribution, contact:

Craig Smith, Senior Editor
Elsevier Supplement Division
360 Park Avenue South
New York, NY 10010
Tel: 212-462-1933;
Fax: 212-633-3820
Email: c.smith@elsevier.com